Sustainability | November 15, 2021
Roche retains its sustainability ranking in the Dow Jones Sustainability Indices
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The company will provide the technical and financial resources to support the study
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Subscribe To Our Newsletter & Stay Updated
